Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
News|Articles|September 3, 2024
Presenting Our September Theme: Forensic Psychiatry
Author(s)Leah Kuntz
Write to us now to be part of our series on forensic psychiatry!
Advertisement
This year, Psychiatric Times® is featuring monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our September theme is forensic psychiatry, which will include expert discussions on the most pressing issues in correctional mental health care and legal complexities in mental health practice.
Are you a forensic mental health clinician? What do you wish we were covering? Let us know! Write to us now at
Advertisement
Related to this article
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Spot SVT or POTS masquerading as panic attacks—key heart-rate clues, home maneuvers, and why anxiety can persist even after arrhythmia treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5